- Home
- ARQT vs AVDX Comparison
ARQT vs AVDX Comparison
Compare ARQT & AVDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- AVDX
- Stock Information
- Founded
- ARQT 2016
- AVDX 2000
- Country
- ARQT United States
- AVDX United States
- Employees
- ARQT N/A
- AVDX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- AVDX EDP Services
- Sector
- ARQT Health Care
- AVDX Technology
- Exchange
- ARQT Nasdaq
- AVDX Nasdaq
- Market Cap
- ARQT 1.6B
- AVDX 1.5B
- IPO Year
- ARQT 2020
- AVDX 2021
- Fundamental
- Price
- ARQT $13.52
- AVDX $9.72
- Analyst Decision
- ARQT Strong Buy
- AVDX Hold
- Analyst Count
- ARQT 6
- AVDX 15
- Target Price
- ARQT $18.80
- AVDX $10.04
- AVG Volume (30 Days)
- ARQT 2.1M
- AVDX 5.5M
- Earning Date
- ARQT 05-06-2025
- AVDX 05-07-2025
- Dividend Yield
- ARQT N/A
- AVDX N/A
- EPS Growth
- ARQT N/A
- AVDX N/A
- EPS
- ARQT N/A
- AVDX 0.01
- Revenue
- ARQT $212,819,000.00
- AVDX $441,284,000.00
- Revenue This Year
- ARQT $57.99
- AVDX $6.17
- Revenue Next Year
- ARQT $41.24
- AVDX $10.40
- P/E Ratio
- ARQT N/A
- AVDX $1,731.39
- Revenue Growth
- ARQT 100.03
- AVDX 10.46
- 52 Week Low
- ARQT $6.99
- AVDX $6.61
- 52 Week High
- ARQT $17.75
- AVDX $12.93
- Technical
- Relative Strength Index (RSI)
- ARQT 42.59
- AVDX 73.82
- Support Level
- ARQT $12.42
- AVDX $8.12
- Resistance Level
- ARQT $15.67
- AVDX $9.74
- Average True Range (ATR)
- ARQT 0.87
- AVDX 0.22
- MACD
- ARQT -0.03
- AVDX 0.21
- Stochastic Oscillator
- ARQT 33.69
- AVDX 99.16
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.